Clinical Trial

Safety and Preliminary Effectiveness Study of Mesenchymal Stem Cells, HeXell-2020, in Patients With Stable Coronary Artery Disease

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase I/IIa study to investigate the safety, tolerability, and preliminary effectiveness of HeXell-2020 in patients with stable coronary artery disease (CAD). HeXell-2020 is an investigational drug product consisting of allogenic umbilical cord mesenchymal stem cells (UCMSCs) as the drug substance. All enrolled and eligible subjects will receive HeXell-2020 treatment.
Trial Details
NCT Number NCT07137104
Lead Sponsor Hexun Biosciences Co., LTD.
Conditions Coronary Artery Disease
Enrollment 39 participants
Start Date 2025-12-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-22